BLUE (bluebird bio) Additional Paid-In Capital : $4,466.14 Mil(As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Additional Paid-In Capital?

bluebird bio's quarterly additional paid-in capital increased from Mar. 2024 ($4,461.37 Mil) to Jun. 2024 ($4,464.71 Mil) and increased from Jun. 2024 ($4,464.71 Mil) to Sep. 2024 ($4,466.14 Mil).

bluebird bio's annual additional paid-in capital increased from Dec. 2021 ($4,096.40 Mil) to Dec. 2022 ($4,185.99 Mil) and increased from Dec. 2022 ($4,185.99 Mil) to Dec. 2023 ($4,454.76 Mil).

bluebird bio Additional Paid-In Capital Historical Data

The historical data trend for bluebird bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Additional Paid-In Capital Chart

bluebird bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,568.18

4,260.44

4,096.40

4,185.99

4,454.76

bluebird bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Additional Paid-In Capital	Get a 7-Day Free Trial															4,333.59	4,454.76	4,461.37	4,464.71	4,466.14

bluebird bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

bluebird bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of bluebird bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BLUE:Mexico 0HOH:UK

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Executives

Thomas J Klima	officer: Chief Commercial Officer, SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Andrew Obenshain	officer: President of SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A Colvin	officer: Chief Medical Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Christopher Krawtschuk	officer: Chief Financial Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Richard A. Paulson	director	85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Elisabeth Leiderman	director	1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole	officer: SVP, Secy. & General Counsel	C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann	officer: Chief Regulatory Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman	officer: Chief Financial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten	officer: Chief Accounting Officer	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145